

Section 1: Issuer information (mandatory)				
Name of issuer	Rua Bioscience Limited			
Class of Financial Product	Ordinary shares			
NZX ticker code	RUA			
ISIN (If unknown, check on NZX website)	NZRUAE0004S1			
Name of Registry	Computershare Investor Services Limited			
Type of corporate action (Please mark with an X in the relevant box/es)	Share Purchase Plan/retail offer		Renounceable Rights issue or Accelerated Offer	
	Capital reconstruction		Non-Renounceable Rights issue or Accelerated Offer	
	Call		Bonus issue	
	Placement	X		
Record date	NA			
Ex Date (one business day before the Record Date)	NA			
Currency	NZD			
External approvals required before offer can proceed on an unconditional basis?	No			
Details of approvals required	NA			
Section 7: Placement (delete full section if not applicable, or mark rows as N/A if not applicable)*				
Number of Equity Securities to be issued	11,280,843			
Issue price per Equity Security	\$0.025			
Maximum dollar amount of Equity Securities to be issued ¹	\$282,021.08			
Proposed issue date	Thursday, 18 December 2025			

¹ Where the issue price per Equity Security is not fixed, and the number of Equity Securities to be issued is not known, the Issuer should instead indicate the maximum dollar amount of Equity Securities to be issued.

Existing holders eligible to participate ²	Y (limited)
Related Parties eligible to participate ³	N
Basis upon which participation by existing Equity Security holders will be determined	Those existing eligible shareholders who applied for oversubscriptions in relation to Rua's 1 for 3 rights offer announced 3 November 2025.
Purpose(s) for which the Issuer is issuing the Equity Securities	To fund short-term and immediate business operating funding requirements.
Reason for placement rather than a pro-rata rights issue or an offer under a Share Purchase Plan in which the Issuer's existing Equity Security holders would have been eligible to participate	Having offered all shareholders the opportunity to participate in the rights offer, the placement shares represent oversubscriptions in excess of the rights offer amount.
Equity Securities to be issued subject to voluntary escrow	Nil
Number and class of Equity Securities to be issued that will be subject to voluntary escrow and the date from which they will cease to be escrowed	NA
Section 8: Lead Manager and Underwriter (mandatory)	
Lead Manager(s) appointed	N
Name of Lead Manager(s)	NA
Fees, commission or other consideration payable to Lead Manager(s) for acting as lead manager(s)	Nil
Underwritten	N
Name of Underwriter(s)	NA
Extent of underwriting (i.e. amount or proportion of the offer that is underwritten)	NA
Fees, commission or other consideration payable to Underwriter(s) for acting as underwriter(s)	NA

² Issuers should answer Y if existing shareholders are eligible to participate even if their participation is subject to satisfaction of eligibility criteria applying to the placement generally, such as the offer only being made to investors in certain jurisdictions or with a certain status, such as wholesale, sophisticated or professional investors only.

³ Issuers should answer Y if there are no restrictions on participation by Related Parties as a result of their status as Related Parties (i.e. restrictions on participation applying to the placement generally should be disregarded).

Summary of significant events that could lead to the underwriting being terminated	NA
Section 9: Authority for this announcement (mandatory)	
Name of person authorised to make this announcement	Paul Naske
Contact person for this announcement	Paul Naske
Contact phone number	021 445 154
Contact email address	paul.naske@ruabio.com
Date of release through MAP	16/12/2025